Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

PHASE3CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide, long acting release

DRUG

exenatide

Trial Locations (25)

14609

Research Site 053, Rochester

19146

Research Site 152, Philadelphia

27103

Research Site 123, Winston-Salem

27713

Research Site 002, Durham

29651

Research Site 587, Greer

33156

Research Site 057, Miami

40503

Research Site 099, Lexington

43302

Research Site 557, Marion

45219

Research Site 405, Cincinnati

46254

Research Site 149, Indianapolis

48202

Research Site 017, Detroit

55416

Research Site 224, Minneapolis

59701

Research Site 023, Butte

63141

Research Site 312, St Louis

75230

Research Site 015, Dallas

78229

Research Site 009, San Antonio

91436

Research Site 182, Encino

92037

Research Site 171, La Jolla

92161

Research Site 518, San Diego

94598

Research Site 024, Walnut Creek

97239

Research Site 231, Portland

98502

Research Site 108, Olympia

Unknown

Research Site, Colorado Springs

Research Site, Chicago

Research Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY